Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Megerlin

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Annales Pharmaceutiques Francaises|November 27, 2012
[Vaccination and French community pharmacists: from innovative actions to innovative organisations?]F Megerlin
Annales Pharmaceutiques Francaises|October 1, 2013
[Conditional pricing for innovative medicines in France: stop telling about risk-sharing!]F Megerlin
Annales Pharmaceutiques Francaises|May 12, 2020
[Cov19, seroprevalence studies and Individuals Protection Committees: aren't the technological and organizational challenges enough ?]C Huriet, F Megerlin
Annales Pharmaceutiques Francaises|July 15, 2020
[Research activities involving human beings & French governmental order April 2020 within Cov19 context: What input?]C Huriet, F Megerlin
Annales Pharmaceutiques Francaises|September 16, 2014
[Faecal microbiota transplantation in France: what applicable law?]F Megerlin, E Fouassier
Annales Pharmaceutiques Francaises|July 7, 2014
Faecal microbiota transplantation: a sui generis biological drug, not a tissueF Megerlin, E Fouassier, R Lopert, et al.
Annales Pharmaceutiques Francaises|November 27, 2012
[Community pharmacist and vaccination: actuality and opportunity]R Moreau, H Lepage, F Blanchet, et al.
Annales Pharmaceutiques Francaises|October 9, 2016
Benefits of pharmacist-led flu vaccination services in community pharmacyC L Kirkdale, G Nebout, F Megerlin, et al.
Annales Pharmaceutiques Francaises|September 16, 2014
[Why could gut microbiota become a medication?]P Bourlioux, F Megerlin, G Corthier, et al.
Annales Pharmaceutiques Francaises|April 1, 2015
[Fecal microbiota transplantation in recurrent Clostridium difficile infections. Framework and pharmaceutical preparation aspects]R Batista, N Kapel, F Megerlin, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Annales Pharmaceutiques Francaises|November 27, 2012
[Vaccination and French community pharmacists: from innovative actions to innovative organisations?]F Megerlin
Annales Pharmaceutiques Francaises|October 1, 2013
[Conditional pricing for innovative medicines in France: stop telling about risk-sharing!]F Megerlin
Annales Pharmaceutiques Francaises|May 12, 2020
[Cov19, seroprevalence studies and Individuals Protection Committees: aren't the technological and organizational challenges enough ?]C Huriet, F Megerlin
Annales Pharmaceutiques Francaises|July 15, 2020
[Research activities involving human beings & French governmental order April 2020 within Cov19 context: What input?]C Huriet, F Megerlin
Annales Pharmaceutiques Francaises|September 16, 2014
[Faecal microbiota transplantation in France: what applicable law?]F Megerlin, E Fouassier
Annales Pharmaceutiques Francaises|July 7, 2014
Faecal microbiota transplantation: a sui generis biological drug, not a tissueF Megerlin, E Fouassier, R Lopert, et al.
Annales Pharmaceutiques Francaises|November 27, 2012
[Community pharmacist and vaccination: actuality and opportunity]R Moreau, H Lepage, F Blanchet, et al.
Annales Pharmaceutiques Francaises|October 9, 2016
Benefits of pharmacist-led flu vaccination services in community pharmacyC L Kirkdale, G Nebout, F Megerlin, et al.
Annales Pharmaceutiques Francaises|September 16, 2014
[Why could gut microbiota become a medication?]P Bourlioux, F Megerlin, G Corthier, et al.
Annales Pharmaceutiques Francaises|April 1, 2015
[Fecal microbiota transplantation in recurrent Clostridium difficile infections. Framework and pharmaceutical preparation aspects]R Batista, N Kapel, F Megerlin, et al.
Pageof 2